Sjöström P A, Kron B G, Odlind B G
Department of Internal Medicine, Orebro Medical Center Hospital, Sweden.
Clin Nephrol. 1995 Jan;43 Suppl 1:S38-41.
We have investigated the pharmacokinetic determinants of delivery of furosemide to its site of action in the renal tubules in patients and healthy volunteers. The bioavailability of furosemide is low and variable. Patients with renal disease may also have a low renal extraction of furosemide. In clinically relevant concentrations the free fraction of furosemide is inversely proportional to the plasma albumin concentration. A change in the free fraction of furosemide will change Clr, Clnr, and Vd in the same direction and that will cause minimal changes in the excretion rate of furosemide and its t1/2. A change in RBF will change the secretory clearance of furosemide to the same proportion and consequently also the excretion rate and its t1/2.
我们已经研究了在患者和健康志愿者中,呋塞米输送至肾小管作用部位的药代动力学决定因素。呋塞米的生物利用度较低且存在变异性。肾病患者对呋塞米的肾脏摄取率也可能较低。在临床相关浓度下,呋塞米的游离分数与血浆白蛋白浓度成反比。呋塞米游离分数的变化将使肾清除率(Clr)、非肾清除率(Clnr)和分布容积(Vd)发生同向变化,且这将导致呋塞米排泄率及其半衰期(t1/2)的变化极小。肾血流量(RBF)的变化将使呋塞米的分泌清除率发生相同比例的变化,进而也使排泄率及其半衰期发生变化。